Author

Francesca Sansi

Observed names: F Sansi, F. Sansi

Institution: Newron Pharmaceuticals (Italy)

Observed institution: Newron Pharmaceuticals (Italy)

ORCID: 0009-0002-4495-5821

Observed ORCID: 0009-0002-4495-5821

OpenAlex ID: A5107662127

Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial

2024 · Ravi Anand, Alessio Turolla, et al. · Neuropharmacology · 16

Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trials

2026 · Ravi Anand, Alessio Turolla, et al. · Therapeutic Advances in Psychopharmacology · 2

545. Targeting negative and cognitive symptoms in schizophrenia: discussion of novel preclinical and clinical findings with evenamide

2026 · R Anand, A Turolla, et al. · The International Journal of Neuropsychopharmacology

526. Translating glutamate modulation into clinical advances for patients with treatment-resistant schizophrenia: challenges and updates from the ENIGMA-TRS phase 3 program

2026 · R Anand, A Turolla, et al. · The International Journal of Neuropsychopharmacology

PDF

Unique benefits of evenamide on social functioning and life engagement in patients with TRS, confirmed in a placebo-controlled study in inadequate responders

2026 · R. Anand, A. Turolla, et al. · European Psychiatry

PDF

Effects of evenamide in a neurodevelopmental animal model of schizophrenia suggest potential sustained clinical benefit

2026 · R. Anand, A. Turolla, et al. · European Psychiatry

PDF

ENIGMA-TRS phase 3 trial: designing and implementing a global study of evenamide in treatment-resistant schizophrenia

2026 · R. Anand, A. Turolla, et al. · European Psychiatry

PDF

Evenamide Phase 3 Program: Study 023 (ENIGMA-TRS) evaluates the efficacy of add-on glutamate modulation in patients with documented treatment-resistant schizophrenia

2026 · R. Anand, A. Turolla, et al. · Neuroscience Applied

Glutamate modulation by evenamide produces statistically significant and clinically relevant improvement in patients with treatment-resistant schizophrenia

2026 · R. Anand, A. Turolla, et al. · Neuroscience Applied

297. Design of a Phase 3, Potentially Pivotal, International, Randomized, Double-blind, Placebo-controlled Trial With Evenamide, a Glutamate Modulator, Add-on to Sga in Patients With Treatment-resistant Schizophrenia

2025 · R Anand, A Turolla, et al. · The International Journal of Neuropsychopharmacology

PDF

315. Evenamide, a Glutamate Modulator, Provided Statistically Significant Benefits When Added to Sga in Patients With Schizophrenia: Phase 2/3, International, Randomized, Double-blind, Placebo-controlled Study Results

2025 · R Anand, A Turolla, et al. · The International Journal of Neuropsychopharmacology

PDF

Efficacy and Safety of Evenamide, a glutamate modulator: Results from a Phase 2/3, international, randomized, double-blind, placebo-controlled add-on trial

2025 · R. Anand, A. Turolla, et al. · European Psychiatry

PDF

Phase 3 program of evenamide, a glutamate release modulator, as add-on in patients with treatment-resistant schizophrenia: design of a potentially pivotal, international, randomized, double-blind, placebo-controlled trial

2025 · R. Anand, A. Turolla, et al. · European Psychiatry

PDF

Evenamide, as an Add-on to Antipsychotics, Produces Long- Lasting Clinically Meaningful Benefit and Converts Treatment- Resistant Schizophrenia (trs) Patients Into a Responsive State: 6-month Results From an Ongoing International Randomized Study

2025 · *Ravi Anand, Alessio Turolla, et al. · The International Journal of Neuropsychopharmacology

PDF

Achievement of clinically meaningful response and remission in treatment-resistant schizophrenia patients: results from a long-term international study with evenamide add-on

2024 · R. Anand, A. Turolla, et al. · Neuroscience Applied

Evenamide as an add-on to antipsychotics demonstrates significant efficacy in patients with schizophrenia in a potentially pivotal randomized placebo-controlled trial

2024 · R. Anand, A. Turolla, et al. · Neuroscience Applied

Works count: 16

Citation count: 18

H-index: 2

I10-index: 1